Abstract 3186
Background
Nasopharyngeal is relatively prevalent in South East Asia and mainland China, northern Africa and Alaska. For advanced disease, there is a greater than 50% risk of recurrence after radiotherapy (RT) alone, and approx. half of all recurrences are distant failures. A meta-analysis of 6 randomized trials showed that addition of chemotherapy (CT) to RT significantly improved disease-free/ progression-free survival rates by 34% to 40% respectively. Epstein-Barr virus (EBV) has yielded significant insight into pathogenesis of NPC. It is undifferentiated form of NPC that shows most consistent worldwide association with EBV suggesting that targeted approaches should be considered for preventive and therapeutic intervention. The prognostic value of pre-treatment EBV DNA viral load for non-endemic areas proved in retrospective study conducted in Italy, disease free survival (DFS) and over all survival (OS) were significantly longer in patients with pre-treatment negative EBV DNA than in positive patients. Antiviral drugs have been used to inhibit EBV replication and target viral DNA polymerase Aim of this study is to define the efficacy of adding anti-viral treatment to eliminate PCR-DNA EBV in patients with NPC. It will also be correlated with the response rate (RR), local control, DFS, and OS.
Trial design
Patients and Methods: All patients with diagnosis of nasopharyngeal squamous cell carcinoma, . Patients should have positive PCR-DNA EBV. Patients will receive concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions. Randomization to antiviral therapy acyclovir tablets 800 mg/day during the whole course of treatment Or Placebo. We aim to enroll 100 patients for study with 2:1 randomization. Follow up with PCR-DNA EBV will be done mid-treatment and immediately after treatment then with usual follow up of the NPC cases.
Clinical trial identification
Legal entity responsible for the study
Radiation oncology Department, Kuwait Cancer Control Center.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1310 - Lymphocytes express receptor tyrosine kinases in patients with renal cell carcinoma and healthy donors
Presenter: Ilya Tsimafeyeu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1596 - Oncogenes analysis using GO-based clustering
Presenter: Dmitriy Babenko
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5181 - PNU-74654 enhances the antiproliferative effects of 5-FU in breast cancer and antagonizes thrombin induced cell growth via the Wnt Pathway
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3344 - P21 has the potential to become the monitoring marker for the CDK4/6 inhibitors resistance in breast cancer
Presenter: Masafumi Iida
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
894 - Overexpression of NAMPT in adult T-cell leukemia/lymphoma patients and anti-tumor activity of a NAMPT inhibitor in vivo
Presenter: Tomohiro Kozako
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2224 - 9-ING-41, a clinically relevant inhibitor of Glycogen Synthase Kinase-3 (GSK-3), is active pre-clinically in human bladder and renal cell cancers
Presenter: Hiroo Kuroki
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3380 - A new natural compound identified with metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab
Presenter: Vincenzo De Falco
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4713 - Multiple Myeloma Metal Levels and Proteasome Activity
Presenter: Kai Uwe Stumpf
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4134 - A translational drug-screening tool for interrogating the effect of anti-TGF-_ therapy on fibroblast activity and the desmoplastic reaction
Presenter: Neel Nissen
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2736 - Eribulin demonstrate selectively high sensitivity to recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) cells and xenograft tumors
Presenter: hiroko kitahara
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract